OBJECTIVE: The aim of this study was to evaluate long-term hearing preservation after gamma knife radiosurgery (GKS) for vestibular schwannomas in patients with initially normal or subnormal hearing (Gardner-Robertson Class 1) and to determine the predictive factors for functional hearing preservation. METHODS: Since July 1992, more than 2053 vestibular schwannomas have been treated by GKS and followed at the Timone University Hospital, Marseille. A minimum of 3 years of follow-up (range, 3-11 years; median, 48 months) is available for 74 patients (without neurofibromatosis Type 2 or previous surgery) with Gardner-Robertson Class 1 hearing. RESULTS: The average age of the patients was 47.5 years (range, 17-76 years). The number of tumors in Koos Stage I was 8, the average number in Stage II was 21, the average number in Stage III was 43, and the average number in Stage IV was 2. The median number of isocenters was 8 (range, 2-45), and the median marginal dose was 12 Gy (range, 9-13 Gy). At the time of the last follow-up evaluation, 78.4% of the patients had preserved functional hearing. Tumor control was achieved in 93% of the cases. The probability of preserving functional hearing was higher in patients who had an initial symptom other than hearing decrease (91.1%), in patients younger than 50 years (83.7%), and in those treated with a dose to the cochlea of less than 4 Gy (90.9%). CONCLUSION: This study shows that the probability of preserving functional hearing in the long term after GKS for patients presenting with unilateral vestibular schwannomas is very high. The positive predictive factors appear to be young age, an initial symptom other than hearing decrease, and a low dose to the cochlea.
OBJECTIVE: The aim of this study was to evaluate long-term hearing preservation after gamma knife radiosurgery (GKS) for vestibular schwannomas in patients with initially normal or subnormal hearing (Gardner-Robertson Class 1) and to determine the predictive factors for functional hearing preservation. METHODS: Since July 1992, more than 2053 vestibular schwannomas have been treated by GKS and followed at the Timone University Hospital, Marseille. A minimum of 3 years of follow-up (range, 3-11 years; median, 48 months) is available for 74 patients (without neurofibromatosis Type 2 or previous surgery) with Gardner-Robertson Class 1 hearing. RESULTS: The average age of the patients was 47.5 years (range, 17-76 years). The number of tumors in Koos Stage I was 8, the average number in Stage II was 21, the average number in Stage III was 43, and the average number in Stage IV was 2. The median number of isocenters was 8 (range, 2-45), and the median marginal dose was 12 Gy (range, 9-13 Gy). At the time of the last follow-up evaluation, 78.4% of the patients had preserved functional hearing. Tumor control was achieved in 93% of the cases. The probability of preserving functional hearing was higher in patients who had an initial symptom other than hearing decrease (91.1%), in patients younger than 50 years (83.7%), and in those treated with a dose to the cochlea of less than 4 Gy (90.9%). CONCLUSION: This study shows that the probability of preserving functional hearing in the long term after GKS for patients presenting with unilateral vestibular schwannomas is very high. The positive predictive factors appear to be young age, an initial symptom other than hearing decrease, and a low dose to the cochlea.
Authors: Erika Ann Woodson; Ryan Douglas Dempewolf; Samuel Paul Gubbels; Aaron Thomas Porter; Jacob Jay Oleson; Marlan Rex Hansen; Bruce Jay Gantz Journal: Otol Neurotol Date: 2010-09 Impact factor: 2.311
Authors: Andrew J Schumacher; Rohan R Lall; Rishi R Lall; Allan Nanney; Amit Ayer; Samir Sejpal; Benjamin P Liu; Maryanne Marymont; Plato Lee; Bernard R Bendok; John A Kalapurakal; James P Chandler Journal: J Neurol Surg B Skull Base Date: 2016-05-31
Authors: Benjamin J Arthurs; Robert K Fairbanks; John J Demakas; Wayne T Lamoreaux; Neil A Giddings; Alexander R Mackay; Barton S Cooke; Ameer L Elaimy; Christopher M Lee Journal: Neurosurg Rev Date: 2011-02-09 Impact factor: 3.042
Authors: Debnarayan Dutta; S Balaji Subramanian; V Murli; H Sudahar; P G Gopalakrishna Kurup; Mahadev Potharaju Journal: J Neurooncol Date: 2011-09-04 Impact factor: 4.130
Authors: Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300